Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2022 17:37 ET | Source: Telix Pharmaceuticals Limited

ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment

MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...
December 20, 2021 16:45 ET | Source: Telix Pharmaceuticals Limited

First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announce that...
October 04, 2021 17:34 ET | Source: Telix Pharmaceuticals Limited

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
August 17, 2021 21:26 ET | Source: Telix Pharmaceuticals Limited

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...
June 22, 2021 19:22 ET | Source: Telix Pharmaceuticals Limited

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of...